MDCO Share Price

Open 35.25 Change Price %
High 35.72 1 Day -0.11 -0.31
Low 35.01 1 Week -1.20 -3.28
Close 35.39 1 Month -4.08 -10.34
Volume 615212 1 Year -3.06 -7.96
52 Week High 55.95
52 Week Low 30.80
MDCO Important Levels
Resistance 2 36.05
Resistance 1 35.78
Pivot 35.37
Support 1 35.00
Support 2 34.73
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 -13.33%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
ARCI 1.45 137.70%
FALC 0.40 60.00%
AMCF 0.03 50.00%
LOCM 0.09 50.00%
OPXAW 0.10 42.86%
VRTA 4.50 38.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

The Medicines Company (NASDAQ: MDCO)

MDCO Technical Analysis 5
As on 21st Aug 2017 MDCO Share Price closed @ 35.39 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 41.12 & Strong Sell for SHORT-TERM with Stoploss of 37.91 we also expect STOCK to react on Following IMPORTANT LEVELS.
MDCO Target for August
1st Target up-side 42.1
2nd Target up-side 44.65
3rd Target up-side 47.21
1st Target down-side 34.8
2nd Target down-side 32.25
3rd Target down-side 29.69
MDCO Other Details
Segment EQ
Market Capital 1165638144.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
MDCO Address
MDCO
N/A
MDCO Latest News
Interactive Technical Analysis Chart The Medicines Company ( MDCO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on The Medicines Company
MDCO Business Profile
The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products. In January 2013, the Company acquired Incline Therapeutics Inc. Effective August 5, 2013, The Medicines Company acquired the entire interest of ProFibrix BV, a biotechnology company. Effective December 4, 2013, The Medicines Co acquired Rempex Pharmaceuticals Inc.